Código QR

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer

Abstract Background Pancreatic ductal adenocarcinoma (PDAC) is often driven by KRAS mutations, but inhibitors targeting the most frequent KRAS substitutions in PDAC are not yet approved in the clinic. We previously discovered that KRAS-mutant PDAC is sensitive to the combination of SHP2 and ERK inhi...

Descrición completa

Gardado en:
Principais autores: Antonio Mulero-Sánchez, Astrid Bosma, Bonifiya Visuvasam, Niki Pouliopoulou, Marieke van de Ven, Natalie Proost, Manon Boeije, Cor Lieftink, Roderick Beijersbergen, Rene Bernards, Sara Mainardi
Formato: Artigo
Idioma:Inglês
Publicado: BMC 2026-01-01
Series:Journal of Experimental & Clinical Cancer Research
Assuntos:
Targeted therapy
Resistance
K-RAS
SHP2
ERK
JUN
Acceso en liña:https://doi.org/10.1186/s13046-025-03616-z
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares